VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA) & Some Key Catalysts Approaching
The obesity stocks are perhaps some of the most discussed and followed stocks in the entire biotechnology sector.
Posts Tagged ‘Orexigen Therapeutics Inc. (OREX)’
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): Anti-Obesity Stocks Are Attractively Priced
The obesity market was one of the most attractive sectors a year ago, and the shares of companies developing anti-obesity drugs were the pharmaceutical sector's hottest properties...
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA), and How Doctors Actually Diagnose Obesity
The obesity crisis in America is a hotly debated topic. According to the Centers for Disease Control and Prevention, more than 35% of adults in the U.S.
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): Ten Flabbergasting Costs of America’s Obesity Epidemic
Obesity is costing us big time. Three times more Americans are obese now than were in 1960. Six times more Americans are now extremely obese than a half-century ago.
Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS): Which Obesity Drug Will Boost Your Portfolio?
In 2012, the FDA approved two obesity drugs for use in the United States. One drug, named "Belviq", is from Arena Pharmaceuticals, Inc.
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA), Orexigen Therapeutics, Inc. (OREX): The Big Weight-Drug Wait
"Wait" seems to be the operative word for the obesity drug industry these days. Investors in VIVUS, Inc.
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): Is Obesity Really a Dangerous Disease?
Obesity drugmakers Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) , VIVUS, Inc. (NASDAQ:VVUS) , and Orexigen Therapeutics, Inc.
5 Hidden Causes of Obesity: Arena Pharmaceuticals, Inc. (ARNA), VIVUS Inc. (VVUS)
Obesity-drug makers Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), VIVUS Inc. (NASDAQ:VVUS), and Orexigen Therapeutics, Inc.
Tick Tock Goes the Obesity Clock: Orexigen Therapeutics, Inc. (OREX), VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA)
The Food and Drug Administration made the company run a clinical trial to confirm that there weren't any heart-related complications with Contrave.
Is the Wait Over? – Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS), Orexigen Therapeutics, Inc. (OREX)
The obesity industry is new on the stock block, but it has already become one of the most followed industries in our market.
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): Is There a “First-Mover” Advantage in Biotech?
The early bird gets the worm. Business gurus might not use that old phrase, but many of them tout the principle behind it.
3 Humongous Health-Care Stocks Last Week: Orexigen Therapeutics, Inc. (OREX), Optimer Pharmaceuticals, Inc. (OPTR)
While the overall market seemed to be deciding this week whether to keep the rally going or take a break, several stocks in the world of health care left no doubt.
VIVUS, Inc. (VVUS), Arena Pharmaceuticals Inc. (ARNA): Just 12,500% More Growth for an Obesity Blockbuster
Of course, that's kind of like talking about an huge gnat. I'm sure they probably exist, but you're working from such a small base, that the added size doesn't amount to much.
The FDA Made Biotech Investing Harder (But More Lucrative): Johnson & Johnson (JNJ)
For instance, it's hard to make money on shoo-in Food and Drug Administration approvals. The approval is already reflected in the price.
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): Will There Ever Be an Obesity Drug Blockbuster?
Investors are anxiously waiting for the launch of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Eisai's obesity drug Belviq, which will match up with VIVUS, Inc.
Arena Pharmaceuticals, Vivus Inc, and the Weight-loss Craze
According to a Centers for Disease Control study earlier this year, about 36 percent of Americans are obese.
Daniel Gold’s QVT Financial Raised Stake In $OREX
Daniel Gold’s QVT Financial discloses that it now has 5.29 million shares in Orexigen Therapeutics, Inc. (OREX), corresponding to a 9.82% passive stake.
